Advertisement
FULC vs HRTX
Which Stock Would AI Choose? Fulcrum Therapeutics (FULC) vs. Heron Therapeutics (HRTX) Stock Comparison
Key Takeaways
- FULC is a clinical-stage biotech undergoing a major strategic reset, while HRTX is a commercial-stage biotech with approved, revenue-generating products — two fundamentally different risk profiles.
- Fulcrum discontinued its lead sickle cell program, pociredir, after regulatory feedback on safety, triggering a sharp sell-off and a pivot toward a merger and cash return to shareholders.
- Heron withdrew its 2026 financial guidance amid patent litigation over CINVANTI, its largest product, adding uncertainty to an otherwise growing acute-care portfolio.
- Both names carry elevated, but distinct, risks: FULC faces execution and deal-completion risk, while HRTX faces commercialization, litigation, and low-cash-balance concerns.
- Investors comparing these tickers should weigh a cash-plus-biotech-option structure (FULC) against a revenue-generating but litigation-clouded commercial business (HRTX).
- For more detail, explore FULC Major News and FULC Today's Price Move, along with HRTX Major News and HRTX Today's Price Move.
- You can also explore Trending AI Robots to see how automated strategies currently position across these and other tickers.
Introduction
Biotechnology stocks often attract traders and investors with very different goals, and FULC (Fulcrum Therapeutics) and HRTX (Heron Therapeutics) illustrate that divide clearly. Fulcrum is a clinical-stage company that has pivoted toward a merger and cash distribution after a clinical setback, while Heron is a commercial-stage company selling approved acute-care and oncology products. Comparing the two highlights contrasting risk profiles: one is largely a special-situation and capital-return story, the other a revenue-generation and litigation story. This comparison may be most relevant for investors and traders weighing balance-sheet strength, catalysts, and relative performance in a volatile small-cap healthcare segment.
FULC Overview and Recent Performance
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company historically focused on small-molecule treatments for genetically defined diseases, particularly sickle cell disease. Its recent story has been defined by the discontinuation of pociredir, its lead candidate. After the U.S. Food and Drug Administration (FDA) raised class-level safety concerns regarding PRC2 inhibitors — a group of drugs that target a protein complex involved in gene regulation — the company concluded there was no viable regulatory path forward and halted development. The announcement triggered a sharp single-day decline of roughly 50%, and the company subsequently reduced its workforce substantially and launched a review of strategic alternatives.
In recent weeks, Fulcrum signed an all-stock merger agreement with Slate Medicines, a migraine-focused biotech, alongside a concurrent private investment of approximately $245 million. Under the proposed structure, legacy Fulcrum stockholders would retain a small ownership stake in the combined company and receive a significant cash dividend funded by Fulcrum's balance sheet, which held about $333 million in cash and securities. The combined entity is expected to trade under a new ticker, subject to stockholder and regulatory approvals. As a result, FULC is now best understood as a cash-return vehicle plus a modest stake in a new migraine-focused pipeline, with deal completion as the central near-term catalyst.
HRTX Overview and Recent Performance
Heron Therapeutics is a commercial-stage biotechnology company with a portfolio of approved products aimed at acute-care and oncology settings, including ZYNRELEF (an extended-release local anesthetic), APONVIE (for post-operative nausea and vomiting), and the antiemetics CINVANTI and SUSTOL used to prevent chemotherapy-related nausea. Unlike Fulcrum, Heron generates meaningful product revenue, which provides a different foundation for valuation and sentiment.
Recent market activity around HRTX has been pressured by several factors. The company reported modestly lower net sales in early 2026, partly reflecting seasonal and weather-related disruptions, while growth in APONVIE and ZYNRELEF remained notable. More significantly, Heron withdrew its 2026 net-sales and adjusted EBITDA guidance — a non-GAAP (non-Generally Accepted Accounting Principles) profitability measure — citing uncertainty from ongoing patent litigation over CINVANTI, its largest revenue product, and the potential entry of generic competition. With a relatively low cash position, Heron's near-term narrative centers on defending its oncology franchise while expanding its acute-care product uptake.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights a focused selection of AI trading bots from a much larger library of hundreds of automated strategies trading thousands of tickers. Only the bots judged most suitable for current market conditions earn a place in this section. These bots span different trading styles, strategies, timeframes, performance records, and statistics, and each trades its own set of tickers — so suitability varies by market regime and individual objective. Exploring the Trending AI Robots page can help traders and investors identify which automated approaches are currently gaining traction, including for small-cap healthcare names such as those discussed here.
Head-to-Head Comparison
The most important contrast between FULC and HRTX is structural. Fulcrum is no longer a conventional pipeline story; it is now a balance-sheet and transaction story, with most of its value tied to a cash dividend and a small retained equity stake contingent on closing a merger. Heron, by contrast, is an operating business with real revenue but thinner cash reserves and litigation-driven uncertainty around its largest product.
On growth drivers, the two diverge further. Fulcrum's upside is largely binary and tied to the Slate merger and the eventual success of Slate's preclinical and early-stage migraine assets, which remain unproven clinically. Heron's growth depends on commercial execution of ZYNRELEF and APONVIE, offset by the patent risk surrounding CINVANTI and the weak performance of SUSTOL. On momentum, both stocks have been volatile and broadly negative, but their drivers differ: Fulcrum's decline reflects a scrapped program and restructuring, while Heron's decline reflects guidance withdrawal, litigation, and balance-sheet concerns. From a sector-exposure standpoint, both remain healthcare-biotech names, yet Fulcrum now functions more like a special-situation vehicle, whereas Heron remains a pure commercial-stage operator.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalysts, Tickeron's AI would likely treat these two names with caution and differentiate between them by risk type rather than by a clear directional preference. Heron offers revenue visibility and identifiable growth in select products, but its trend consistency is undermined by litigation uncertainty, withdrawn guidance, and a constrained cash position. Fulcrum offers a more defined near-term catalyst in the form of a pending cash dividend and merger, yet that value is contingent on deal completion and carries a binary execution risk. On balance, an AI-driven framework would probably view Fulcrum's nearer-dated, cash-backed catalyst as more measurable in the short term, while recognizing that neither stock currently exhibits the stable trend characteristics typically favored by trend-following systems. Any preference should therefore be read as probabilistic rather than definitive.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and HRTX is a Buy.
FULC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for FULC turned positive on October 27, 2026. Looking at past instances where FULC's MACD turned positive, the stock continued to rise in 30 of 34 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on FULC as a result. In 67 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +1.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FULC advanced for three days, in 233 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where FULC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
FULC moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FULC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for FULC entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.909) is normal, around the industry mean (3.498). P/E Ratio (-3.058) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.064) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. FULC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FULC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HRTX in upward trend: price rose above 50-day moving average on November 09, 2026
HRTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on HRTX as a result. In 66 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for HRTX just turned positive on November 09, 2026. Looking at past instances where HRTX's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +27.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HRTX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HRTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. HRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FULC | HRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 64 | |
P/E GROWTH RATING 1..100 | 48 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 26 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FULC's Valuation (26) in the null industry is somewhat better than the same rating for HRTX (78) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than HRTX’s over the last 12 months.
FULC's Profit vs Risk Rating (100) in the null industry is in the same range as HRTX (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to HRTX’s over the last 12 months.
FULC's SMR Rating (97) in the null industry is in the same range as HRTX (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to HRTX’s over the last 12 months.
FULC's Price Growth Rating (63) in the null industry is in the same range as HRTX (64) in the Biotechnology industry. This means that FULC’s stock grew similarly to HRTX’s over the last 12 months.
HRTX's P/E Growth Rating (12) in the Biotechnology industry is somewhat better than the same rating for FULC (48) in the null industry. This means that HRTX’s stock grew somewhat faster than FULC’s over the last 12 months.
| FULC | HRTX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Advances ODDS (%) | 3 days ago 86% | 2 days ago 85% |
| Declines ODDS (%) | 10 days ago 81% | 13 days ago 89% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FULC’s FA Score shows that 1 FA rating(s) are green while HRTX’s FA Score has 1 green FA rating(s).
- FULC’s FA Score: 1 green, 4 red.
- HRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FULC’s TA Score shows that 3 TA indicator(s) are bullish while HRTX’s TA Score has 5 bullish TA indicator(s).
- FULC’s TA Score: 3 bullish, 4 bearish.
- HRTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
FULC (@Biotechnology) experienced а -0.53% price change this week, while HRTX (@Biotechnology) price change was +31.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
FULC is expected to report earnings on Nov 11, 2026.
HRTX is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FULC and
Correlation & Price change
A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ABVX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ABVX could also see price increases.
| Ticker / NAME | Correlation To FULC | 1D Price Change % | ||
|---|---|---|---|---|
| FULC | 100% | N/A | ||
| ABVX - FULC | 57% Loosely correlated | +3.45% | ||
| SLS - FULC | 48% Loosely correlated | -2.45% | ||
| HRTX - FULC | 47% Loosely correlated | +0.94% | ||
| PRAX - FULC | 45% Loosely correlated | +1.39% | ||
| WVE - FULC | 41% Loosely correlated | -2.01% | ||
More | ||||
HRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with FULC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To HRTX | 1D Price Change % | ||
|---|---|---|---|---|
| HRTX | 100% | +0.94% | ||
| FULC - HRTX | 47% Loosely correlated | N/A | ||
| AMRN - HRTX | 44% Loosely correlated | +0.09% | ||
| ABVX - HRTX | 44% Loosely correlated | +3.45% | ||
| SION - HRTX | 41% Loosely correlated | +3.64% | ||
| TENX - HRTX | 40% Loosely correlated | -5.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| UFOX | 74.71 | -0.18 | -0.24% |
| Defiance Space and Connective Tech ETF (UFOX) | |||
| VIXY | 18.16 | -0.05 | -0.27% |
| ProShares VIX Short-Term Futures ETF (VIXY) | |||
| JANT | 44.90 | -0.12 | -0.28% |
| AllianzIM U.S. Equity Buffer10 Jan ETF (JANT) | |||
| ABLD | 30.84 | -0.30 | -0.95% |
| Abacus FCF Real Assets Leaders ETF (ABLD) | |||
| TLH | 95.09 | -1.08 | -1.12% |
| iShares 10-20 Year Treasury Bond ETF (TLH) | |||